⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17835201 | 1.00 | — | — | |
| SCHEMBL18269015 | 1.00 | — | — | |
| SCHEMBL11997996 | 0.86 | CHRM3 (0.35) | — | |
| SCHEMBL58010 | 0.86 | CHRM3 (0.35) | — | |
| SCHEMBL463540 | 0.86 | CHRM3 (0.35) | — | |
| SCHEMBL12572936 | 0.84 | KMT2A (0.39) | — | |
| SCHEMBL13452774 | 0.84 | KMT2A (0.39) | — | |
| SCHEMBL20093387 | 0.84 | KMT2A (0.39) | — | |
| SCHEMBL23371066 | 0.82 | KMT2A (0.41) | — | |
| SCHEMBL21398646 | 0.82 | KMT2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230066136-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2022081655-A1 | SUBSTITUTED DIHYDROPYRANOPYRIMIDINE COMPOUNDS AS KRAS INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| WO-2014086723-A1 | USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYLOALKENYL ETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-06-12 | — | — | WO | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |